Effects of Diaphragmatic and Abdominal Neuromuscular Electrical Stimulation in Post-PCI Patients
1 other identifier
interventional
42
0 countries
N/A
Brief Summary
This study is a randomized controlled trial designed to evaluate the effects of combined diaphragmatic and abdominal neuromuscular electrical stimulation (NMES) on arterial blood gases, pulmonary function, left ventricular ejection fraction, and functional capacity in patients following percutaneous coronary intervention (PCI). A total of 42 participants will be randomly allocated into two groups: an intervention group receiving NMES along with standard cardiac rehabilitation, and a control group receiving standard rehabilitation alone. The intervention will be administered for 30 minutes per session, five days per week, over a period of two weeks. Outcome measures will include arterial blood gas parameters (PaO₂, PaCO₂, SaO₂), spirometry indices (FVC, FEV₁, PEFR), ejection fraction assessed by echocardiography, and functional capacity measured using the 6-minute walk test. Assessments will be conducted at baseline and post-intervention. The study aims to determine whether NMES can serve as an effective adjunct to conventional cardiac rehabilitation in improving respiratory and functional outcomes in post-PCI patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started May 2026
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 2, 2026
CompletedStudy Start
First participant enrolled
May 28, 2026
CompletedFirst Posted
Study publicly available on registry
June 5, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 28, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 29, 2026
June 5, 2026
June 1, 2026
1 month
April 2, 2026
June 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (6)
Partial Pressure of Oxygen (PaO₂)
Measurement of arterial partial pressure of oxygen using arterial blood gas analysis.
Baseline and after 2 weeks of intervention
Partial Pressure of Carbon Dioxide (PaCO₂)
Measurement of arterial partial pressure of carbon dioxide using arterial blood gas analysis.
Baseline and after 2 weeks of intervention
Arterial Oxygen Saturation (SaO₂)
Measurement of arterial oxygen saturation using arterial blood gas analysis.
Baseline and after 2 weeks of intervention
Forced Vital Capacity (FVC)
Assessment of forced vital capacity using spirometry.
Baseline and after 2 weeks of intervention
Forced Expiratory Volume in 1 Second (FEV₁)
Assessment of forced expiratory volume in 1 second using spirometry.
Baseline and after 2 weeks of intervention
Peak Expiratory Flow Rate (PEFR)
Assessment of peak expiratory flow rate using spirometry.
Baseline and after 2 weeks of intervention
Secondary Outcomes (1)
Left Ventricular Ejection Fraction (LVEF)
Baseline and after 2 weeks
Study Arms (2)
NMES + Standard Cardiac Rehabilitation
EXPERIMENTALParticipants in this group will receive combined diaphragmatic and abdominal neuromuscular electrical stimulation (NMES) in addition to standard cardiac rehabilitation. NMES will be applied using surface electrodes placed over the lower thoracic region (for diaphragmatic stimulation) and abdominal muscles (rectus abdominis and external obliques). The intervention will be delivered for 30 minutes per session, five days per week, for two weeks, along with routine cardiac rehabilitation including aerobic exercise, breathing exercises, and education.
Standard Cardiac Rehabilitation
ACTIVE COMPARATORParticipants in this group will receive standard cardiac rehabilitation only, including aerobic exercise, breathing exercises, and patient education as per institutional protocol, without the use of neuromuscular electrical stimulation (NMES).
Interventions
A dual-channel electrical stimulation device will be used to deliver stimulation to respiratory muscles. Surface electrodes will be placed over the lower thoracic region for diaphragmatic stimulation and over the abdominal muscles for expiratory muscle stimulation. Stimulation parameters will include a frequency of 30-50 Hz, pulse width of 300 µs, and a duty cycle of 5 seconds on and 5 seconds off. Intensity will be adjusted to achieve visible muscle contraction without discomfort. Sessions will last 30 minutes, five days per week, for two weeks.
A structured cardiac rehabilitation program including aerobic exercise, breathing exercises, and patient education delivered according to institutional protocols, without the use of neuromuscular electrical stimulation.
Eligibility Criteria
You may qualify if:
- Patients aged 40-75 years
- Patients who have undergone successful percutaneous coronary intervention (PCI) for stable or acute coronary syndrome
- Hemodynamically stable (no inotropic support, no active arrhythmias)
- Left ventricular ejection fraction (LVEF) ≥ 35%
- Able to perform spirometry and 6-minute walk test (6MWT)
- Willing to participate and provide informed consent
You may not qualify if:
- Significant arrhythmias or pacemaker/implantable defibrillator not cleared for NMES
- Severe pulmonary disease (e.g., advanced COPD, pulmonary fibrosis) affecting lung function independently
- Neuromuscular disorders interfering with NMES application
- Recent stroke or severe cognitive impairment limiting participation
- Active infection, sepsis, or systemic inflammatory disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Officials
- PRINCIPAL INVESTIGATOR
Arjumand Bano, MS
Riphah International University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Masking Details
- Due to the nature of the intervention, participants and care providers cannot be blinded. However, outcome assessors will be blinded to group allocation to minimize assessment bias.
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 2, 2026
First Posted
June 5, 2026
Study Start
May 28, 2026
Primary Completion (Estimated)
June 28, 2026
Study Completion (Estimated)
June 29, 2026
Last Updated
June 5, 2026
Record last verified: 2026-06
Data Sharing
- IPD Sharing
- Will not share